Global X Robo Global Robotics & Automation ETF (ROBO) Stock Price Today
Aura AI Summary
Key Stats
- $1.78BMarket Cap
- 135,690Volume
- Sector/ThematicSector
- $90.3452W High
- $63.0452W Low
- 45 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 100% Sell | 0% BuyTrading Activity
Track Global X Robo Global Robotics & Automation ETF (ROBO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Global X Robo Global Robotics & Automation ETF has traded between a low of $63.04 and a high of $90.34, highlighting its annual price range. Buy and sell Global X Robo Global Robotics & Automation ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Most Recent News
Trogenix appoints John Young as Chair and Josh Murray as Non-Executive Director to boost global growth and US expansion.
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...

Wellington Management Group crosses 5% voting rights threshold in Admiral Group PLC shares.
Wellington Management Group LLP has notified that it crossed the 5% voting rights threshold in Admiral Group PLC as of November 6, 2026. The group holds a total of 5.01% voting rights through direct shares and financial instruments. This disclosure i...

Roche unveils new Alzheimer’s drug and diagnostic data at CTAD 2026, advancing treatment and early detection.
Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.